Multidimensional analysis reveals predictive markers for CAR-T efficacy

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-06-20 DOI:10.1038/s43018-024-00785-2

Kevin P. Letscher, Sai T. Reddy

引用次数: 0

Abstract

At present, six CAR-T therapies are FDA approved to treat hematological cancers, but not all patients respond. A new study has developed a multidimensional functional profiling method to screen CAR-T cells from patients with large B cell lymphomas in clinical trials and identified a T cell subset associated with successful clinical response.

Abstract Image

查看原文本刊更多论文

多维分析揭示了 CAR-T 疗效的预测指标。

目前，美国食品和药物管理局批准了六种 CAR-T 疗法来治疗血液癌症，但并非所有患者都有反应。一项新研究开发了一种多维功能谱分析方法，用于筛选临床试验中大B细胞淋巴瘤患者的CAR-T细胞，并确定了一种与成功临床应答相关的T细胞亚群。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.